<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814346</url>
  </required_header>
  <id_info>
    <org_study_id>2-39-00240-134</org_study_id>
    <secondary_id>2007-005377-63</secondary_id>
    <nct_id>NCT00814346</nct_id>
  </id_info>
  <brief_title>Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions</brief_title>
  <official_title>Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on
      cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild
      Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory
      complaint patients cognitively normal (CNE). The first phase includes four weeks treatment
      with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18
      FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU)
      period with EGb761® treatment in MC and CNE patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)</measure>
    <time_frame>From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase</time_frame>
    <description>Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l'Energie Atomique (CEA):
The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only)
The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group
FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease.
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80
Standardized Uptake Value (SUV) Body Surface Area (BSA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Glucose Metabolism in the MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Brain glucose metabolism measured by 18FDG PET
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By &quot;yes&quot; or &quot;no&quot; answers, scores permit to classify patients into groups of &quot;severely depressed&quot; (score of 21 to 30), &quot;moderately depressed&quot; (score of 11 to 20) and &quot;normal&quot; (score of 0 to10). It takes10 to 15 minutes to administer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 9</time_frame>
    <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.
The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</measure>
    <time_frame>At Month 9</time_frame>
    <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.
National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)</measure>
    <time_frame>At Month 9</time_frame>
    <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-CDR Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-GDS Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By &quot;yes&quot; or &quot;no&quot; answers, scores permit to classify patients into groups of &quot;severely depressed&quot; (score of 21 to 30), &quot;moderately depressed&quot; (score of 11 to 20) and &quot;normal&quot; (score of 0 to10). It takes10 to 15 minutes to administer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-MMSE Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</measure>
    <time_frame>At Month 18</time_frame>
    <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)</measure>
    <time_frame>At Month 18</time_frame>
    <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to Month 18</time_frame>
    <description>The relationship of an adverse event to the study medication will be classified according to the following criteria:
Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely
Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size</measure>
    <time_frame>From Baseline (Month 0) to Month 18</time_frame>
    <description>Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>EGb 120 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGb761®</intervention_name>
    <description>Four weeks for AD patients, 18 months for MC and CNE patients</description>
    <arm_group_label>EGb 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group Specific Inclusion Criteria:

        Cognitively normal elderly (CNE)

          -  Spontaneous memory complaint by patient,

          -  Mini-Mental State Exam score ≥ 28.

          -  Clinical Dementia Rating = 0.

          -  No Diagnostic And Statistical Manual Of Mental Disorders, Fourth Edition (DSMIV)
             criteria for Dementia.

        Memory complaints (MC) :

          -  Spontaneous memory complaint by patient

          -  Mini-Mental State Exam score ≥ 25

          -  Clinical Dementia Rating 0.5.

          -  No DSMIV criteria for Dementia.

        Mild Alzheimer's Disease (AD):

          -  Mini Mental Status Examination (MMSE) between 20 and 28 (inclusive).

          -  Clinical Dementia Rating ≥ 1.0

          -  DSMIV criteria for Dementia.

          -  National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's
             Disease and Related Disorders Association(NINCDS/ADRDA) criteria for probable AD.

          -  Newly diagnosed patients without treatment by Cholinesterase Inhibitors or Memantine.

          -  ≥ 65 years of age, both sex

          -  Geriatric Depression Scale (GDS) &lt; 15

          -  Informed consent signed by the patient or, if necessary by legal representative

        Exclusion Criteria:

          -  Contraindication to Magnetic Resonance Imaging (MRI) and/or Positron-Emission
             Tomography (PET) scan

          -  Forbidden Concomitant medications (Cholinesterase inhibitors and memantine, Specific
             psychoactive medications,e.g., neuroleptics, chronic anxiolytics including
             meprobamate, or sedative hypnotics other than benzodiazepines, Monoamine oxidase
             inhibitors (MAOIs) including selective MAOIs. Drugs acting on cerebral nervous system,
             Antidiabetes medications , Antioxidants medications, Medications known to interfere
             with cognitive evaluations

          -  Significant neurological disease and psychiatric disorders/psychotic feature

          -  Significant medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Mathiex-Fortunet, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Corentin Celton 4 parvis Corentin Celton</name>
      <address>
        <city>Issy-Les-Moulineaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Juvisy</name>
      <address>
        <city>Juvisy sur Orge</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMPI &quot;Les Rives de Seine&quot;</name>
      <address>
        <city>Le Vesinet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Orsay 4 place du Général Leclerc</name>
      <address>
        <city>Orsay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Paris</city>
        <zip>75009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Broca 54-56 rue Pascal</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Observatoire de l'âge</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <results_first_submitted>September 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Alzheimer's disease (AD) patients</keyword>
  <keyword>Memory complaint patients with cognitive impairment (MC)</keyword>
  <keyword>Memory complaint patients cognitively normal (CNE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 63 participants were screened of which 49 subjects were randomised to either EGb761 and Placebo treatment groups (double-blind period).
The 49 randomised subjects consisted of three groups of elderly subjects: Cognitively normal elderly (CNE), Memory Complaint (MC) and Alzheimer’s Disease (AD).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EGb761 120 mg</title>
          <description>EGb761 120 mg tablet twice a day for 4 weeks (Double-blind phase) for CNE, MC, and AD patients and 17 months (Open phase) for CNE and MC patients</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 1 tablet twice a day for 4 weeks CNE, MC, and AD patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CNE</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MC</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AD</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not otherwise specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Phase (17 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41">Open period was treated with EGB761®. 41 subjects accepted follow-up open period(21 in CNE,20 in MC)</participants>
                <participants group_id="P2" count="0">This was an open period, without placebo arm, the number of subject on placebo is 0.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>CNE</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MC</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AD</title>
              <participants_list>
                <participants group_id="P1" count="0">Open period was not proposed to AD subjects.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not otherwise specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EGb761 120 mg</title>
          <description>EGb761 120 mg tablet twice a day for 4 weeks (Double-blind phase) for CNE, MC, and AD patients and 17 months (Open phase) for CNE and MC patients</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 1 tablet twice a day for 4 weeks CNE, MC, and AD patients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.1" spread="6.2"/>
                    <measurement group_id="B2" value="76.6" spread="5.3"/>
                    <measurement group_id="B3" value="75.85" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.49" spread="4.46"/>
                    <measurement group_id="B2" value="25.03" spread="4.40"/>
                    <measurement group_id="B3" value="24.76" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Level 1: Primary only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 2: School certificate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 3: Completed secondary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 4: University</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brain Glucose Metabolism in the MC and CNE Groups</title>
        <description>Brain glucose metabolism measured by 18FDG PET
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Glucose Metabolism in the MC and CNE Groups</title>
          <description>Brain glucose metabolism measured by 18FDG PET
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>SUVBSA2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.5" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.5" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.2" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.8" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-0.8" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.6" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.5" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.5" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.2" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.3" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.00" lower_limit="-0.9" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.6" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.6" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.5" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.4" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.6" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.3" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups</title>
        <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patient</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups</title>
          <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>CDR overall score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups</title>
        <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By “yes” or “no” answers, scores permit to classify patients into groups of “severely depressed” (score of 21 to 30), “moderately depressed” (score of 11 to 20) and “normal” (score of 0 to10). It takes10 to 15 minutes to administer.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups</title>
          <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By “yes” or “no” answers, scores permit to classify patients into groups of “severely depressed” (score of 21 to 30), “moderately depressed” (score of 11 to 20) and “normal” (score of 0 to10). It takes10 to 15 minutes to administer.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>GDS Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" lower_limit="-6.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</title>
        <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</title>
          <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Number of good answers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Categorical verbal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" lower_limit="-14.0" upper_limit="11.0"/>
                    <measurement group_id="O2" value="-2.00" lower_limit="-16.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lexical verbal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-14.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="-18.0" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)</title>
        <description>Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l’Energie Atomique (CEA):
The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only)
The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group
FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease.
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80
Standardized Uptake Value (SUV) Body Surface Area (BSA)</description>
        <time_frame>From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase</time_frame>
        <population>Intention to treat (ITT) population: All treated CNE and MC patients</population>
        <group_list>
          <group group_id="O1">
            <title>EGb761 120 mg (CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 4 weeks (Double-blind phase) for CNE, MC, and AD patients</description>
          </group>
          <group group_id="O2">
            <title>Placebo (CNE)</title>
            <description>Placebo 1 tablet twice a day for 4 weeks for CNE, MC and AD patients</description>
          </group>
          <group group_id="O3">
            <title>EGb761 120 mg (MC)</title>
            <description>EGb761 120 mg tablet twice a day for 4 weeks (Double-blind phase) for CNE, MC, and AD patients</description>
          </group>
          <group group_id="O4">
            <title>Placebo (MC)</title>
            <description>Placebo 1 tablet twice a day for 4 weeks for CNE, MC and AD patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)</title>
          <description>Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l’Energie Atomique (CEA):
The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only)
The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group
FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease.
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80
Standardized Uptake Value (SUV) Body Surface Area (BSA)</description>
          <population>Intention to treat (ITT) population: All treated CNE and MC patients</population>
          <units>SUVBSA2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.40" lower_limit="-16.4" upper_limit="18.7"/>
                    <measurement group_id="O2" value="-1.07" lower_limit="-22.8" upper_limit="33.5"/>
                    <measurement group_id="O3" value="-7.58" lower_limit="-29.7" upper_limit="26.4"/>
                    <measurement group_id="O4" value="-3.09" lower_limit="-16.4" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.56" lower_limit="-14.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="2.25" lower_limit="-28.9" upper_limit="35.9"/>
                    <measurement group_id="O3" value="0.44" lower_limit="-36.3" upper_limit="35.8"/>
                    <measurement group_id="O4" value="-0.32" lower_limit="-33.9" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.46" lower_limit="-23.3" upper_limit="25.1"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-39.6" upper_limit="37.4"/>
                    <measurement group_id="O3" value="-2.09" lower_limit="-35.2" upper_limit="30.1"/>
                    <measurement group_id="O4" value="-6.19" lower_limit="-38.9" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" lower_limit="-28.0" upper_limit="29.1"/>
                    <measurement group_id="O2" value="4.60" lower_limit="-23.8" upper_limit="49.6"/>
                    <measurement group_id="O3" value="2.16" lower_limit="-35.8" upper_limit="53.4"/>
                    <measurement group_id="O4" value="3.27" lower_limit="-51.4" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" lower_limit="-23.7" upper_limit="26.3"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-23.5" upper_limit="55.8"/>
                    <measurement group_id="O3" value="2.15" lower_limit="-46.0" upper_limit="46.2"/>
                    <measurement group_id="O4" value="-6.20" lower_limit="-49.1" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="-53.5" upper_limit="19.7"/>
                    <measurement group_id="O2" value="-7.29" lower_limit="-30.4" upper_limit="67.5"/>
                    <measurement group_id="O3" value="2.37" lower_limit="-22.3" upper_limit="24.4"/>
                    <measurement group_id="O4" value="-4.62" lower_limit="-53.8" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" lower_limit="-26.3" upper_limit="19.4"/>
                    <measurement group_id="O2" value="-1.26" lower_limit="-9.4" upper_limit="39.2"/>
                    <measurement group_id="O3" value="-7.75" lower_limit="-28.5" upper_limit="14.0"/>
                    <measurement group_id="O4" value="-8.72" lower_limit="-24.7" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.49" lower_limit="-25.3" upper_limit="21.4"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-29.4" upper_limit="38.2"/>
                    <measurement group_id="O3" value="-7.11" lower_limit="-32.5" upper_limit="35.5"/>
                    <measurement group_id="O4" value="-6.59" lower_limit="-36.1" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.40" lower_limit="-27.3" upper_limit="28.7"/>
                    <measurement group_id="O2" value="-2.05" lower_limit="-46.6" upper_limit="41.5"/>
                    <measurement group_id="O3" value="-3.87" lower_limit="-29.9" upper_limit="28.1"/>
                    <measurement group_id="O4" value="-7.72" lower_limit="-43.4" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" lower_limit="-36.2" upper_limit="29.1"/>
                    <measurement group_id="O2" value="-0.66" lower_limit="-23.7" upper_limit="46.0"/>
                    <measurement group_id="O3" value="-9.21" lower_limit="-34.2" upper_limit="40.9"/>
                    <measurement group_id="O4" value="-6.45" lower_limit="-41.3" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.31" lower_limit="-42.9" upper_limit="30.8"/>
                    <measurement group_id="O2" value="-2.73" lower_limit="-39.1" upper_limit="52.8"/>
                    <measurement group_id="O3" value="-8.84" lower_limit="-41.7" upper_limit="41.8"/>
                    <measurement group_id="O4" value="-5.36" lower_limit="-50.4" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.08" lower_limit="-23.8" upper_limit="32.8"/>
                    <measurement group_id="O2" value="-0.76" lower_limit="-43.7" upper_limit="41.5"/>
                    <measurement group_id="O3" value="-8.21" lower_limit="-27.6" upper_limit="65.5"/>
                    <measurement group_id="O4" value="-0.59" lower_limit="-51.4" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" lower_limit="-21.1" upper_limit="17.3"/>
                    <measurement group_id="O2" value="-1.72" lower_limit="-22.1" upper_limit="40.4"/>
                    <measurement group_id="O3" value="-5.99" lower_limit="-23.0" upper_limit="33.7"/>
                    <measurement group_id="O4" value="-1.24" lower_limit="-35.0" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups</title>
        <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups</title>
          <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>MMSE Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-6.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</title>
        <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</title>
          <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Clock drawing test score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</title>
        <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</title>
          <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Cube drawing test score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)</title>
        <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)</title>
          <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Recall score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Immediate Recall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-1.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-10.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Delayed Recall Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</title>
        <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</title>
          <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Age adjusted score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-5.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-4.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups</title>
        <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups</title>
          <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Age adjusted score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-3.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-3.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups</title>
        <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.
The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
        <time_frame>From Baseline (Month 0) to Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups</title>
          <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.
The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Task A (N=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-43.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="2.50" lower_limit="-18.0" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Task B (N=17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-200.0" upper_limit="56.0"/>
                    <measurement group_id="O2" value="-5.50" lower_limit="-57.0" upper_limit="113.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</title>
        <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.
National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA)</description>
        <time_frame>At Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</title>
          <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.
National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA)</description>
          <population>ITT population. N=Number of subjects with assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer’s)</title>
        <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
        <time_frame>At Month 9</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer’s)</title>
          <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-CDR Score in MC and CNE Groups</title>
        <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-CDR Score in MC and CNE Groups</title>
          <description>CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>CDR overall score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-GDS Score in MC and CNE Groups</title>
        <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By “yes” or “no” answers, scores permit to classify patients into groups of “severely depressed” (score of 21 to 30), “moderately depressed” (score of 11 to 20) and “normal” (score of 0 to10). It takes10 to 15 minutes to administer.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-GDS Score in MC and CNE Groups</title>
          <description>The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By “yes” or “no” answers, scores permit to classify patients into groups of “severely depressed” (score of 21 to 30), “moderately depressed” (score of 11 to 20) and “normal” (score of 0 to10). It takes10 to 15 minutes to administer.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>GDS Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-7.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-5.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</title>
        <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (Open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups</title>
          <description>Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Number of good answers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>categorical verbal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-18.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-9.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lexical verbal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-16.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="-7.0" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-MMSE Score in MC and CNE Groups</title>
        <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-MMSE Score in MC and CNE Groups</title>
          <description>MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>MMSE Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</title>
        <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups</title>
          <description>Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Clock drawing test score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</title>
        <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups</title>
          <description>Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Cube drawing test score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-6.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT</title>
        <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT</title>
          <description>Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Recall score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Immediate Recall Score of FCSRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-3.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="-4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Delayed Recall Score of FCSRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-6.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</title>
        <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups</title>
          <description>Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Age adjusted score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups</title>
        <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups</title>
          <description>Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Age adjusted score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-3.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="-2.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups</title>
        <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups</title>
          <description>TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>Seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Task A (N=18,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" lower_limit="-59.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-31.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Task B (N=18,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.50" lower_limit="-213.0" upper_limit="29.0"/>
                    <measurement group_id="O2" value="-9.00" lower_limit="-76.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</title>
        <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.</description>
        <time_frame>At Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)</title>
          <description>The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer’s)</title>
        <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
        <time_frame>At Month 18</time_frame>
        <population>ITT population. N=Number of subjects with assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb 120 mg (Open Phase - CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb 120 mg (Open Phase - MC)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Conversion to Alzheimer’s Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer’s)</title>
          <description>The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.</description>
          <population>ITT population. N=Number of subjects with assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AEs)</title>
        <description>The relationship of an adverse event to the study medication will be classified according to the following criteria:
Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely
Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.</description>
        <time_frame>Up to Month 18</time_frame>
        <population>Safety population. CNE patients withdrew during the double-blind phase and were also not included in the safety population for open phase (17 months).</population>
        <group_list>
          <group group_id="O1">
            <title>EGb761 120 mg (Double-blind Phase)</title>
            <description>EGb761 120 mg twice a day for 4 weeks (double-blind phase) for CNE, MC and AD patients</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-blind Phase)</title>
            <description>Placebo 1 tablet twice a day for 4 weeks (double-blind phase) for CNE, MC and AD patients</description>
          </group>
          <group group_id="O3">
            <title>EGb761 120 mg (Open Phase)</title>
            <description>EGb761 120 mg twice a day for 17 months (open phase) for MC and CNE patients</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs)</title>
          <description>The relationship of an adverse event to the study medication will be classified according to the following criteria:
Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely
Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.</description>
          <population>Safety population. CNE patients withdrew during the double-blind phase and were also not included in the safety population for open phase (17 months).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Treatment Emergent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of Severe Treatment Emergent AEs (TEAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of moderate TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of mild TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causality of Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causality of Non Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Causality and Intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related &amp; severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related &amp; moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related &amp; mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one not related &amp; severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one not related &amp; moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one not related &amp; mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAES Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size</title>
        <description>Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry</description>
        <time_frame>From Baseline (Month 0) to Month 18</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>EGb761 120 mg (CNE)</title>
            <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for CNE patients</description>
          </group>
          <group group_id="O2">
            <title>EGb761 120 mg (MC)</title>
            <description>EGb761 120 mg 17 months (open phase) for MC patients</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size</title>
          <description>Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry</description>
          <population>ITT population.</population>
          <units>mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6454.00" lower_limit="-42470.0" upper_limit="30372.0"/>
                    <measurement group_id="O2" value="6168.50" lower_limit="-38855.2" upper_limit="65345.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5765.50" lower_limit="-52347.0" upper_limit="97071.0"/>
                    <measurement group_id="O2" value="32428.00" lower_limit="-103527" upper_limit="88300.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.20" lower_limit="-418.9" upper_limit="1023.1"/>
                    <measurement group_id="O2" value="24.57" lower_limit="-794.8" upper_limit="780.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.68" lower_limit="-387.3" upper_limit="1105.3"/>
                    <measurement group_id="O2" value="140.97" lower_limit="-827.2" upper_limit="1384.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.14" lower_limit="-346.4" upper_limit="676.4"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-842.6" upper_limit="481.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.26" lower_limit="-99.0" upper_limit="157.6"/>
                    <measurement group_id="O2" value="81.56" lower_limit="-57.4" upper_limit="236.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.75" lower_limit="-86.2" upper_limit="380.4"/>
                    <measurement group_id="O2" value="50.66" lower_limit="-208.7" upper_limit="431.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right cerebral cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5853.00" lower_limit="-40148.0" upper_limit="103200.0"/>
                    <measurement group_id="O2" value="38955.50" lower_limit="-102169" upper_limit="97667.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.83" lower_limit="-715.7" upper_limit="669.6"/>
                    <measurement group_id="O2" value="14.90" lower_limit="-570.1" upper_limit="755.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right caudate nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.74" lower_limit="-274.2" upper_limit="519.6"/>
                    <measurement group_id="O2" value="303.66" lower_limit="-223.5" upper_limit="1084.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right putamen nucleus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" lower_limit="-229.6" upper_limit="663.8"/>
                    <measurement group_id="O2" value="-78.94" lower_limit="-520.5" upper_limit="343.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right ventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.15" lower_limit="-5.5" upper_limit="198.8"/>
                    <measurement group_id="O2" value="70.85" lower_limit="-13.0" upper_limit="287.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right globus pallidus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.68" lower_limit="-293.0" upper_limit="312.6"/>
                    <measurement group_id="O2" value="64.82" lower_limit="-119.3" upper_limit="318.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to month 18 follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EGb761 120 mg (Double-blind Phase)</title>
          <description>EGb761 120 mg tablet twice a day for 4 weeks (double-blind phase) for CNE, MC, and AD patients</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Double-blind Phase)</title>
          <description>Placebo 1 tablet twice a day for 4 weeks (double-blind phase) for CNE, MC, and AD patients</description>
        </group>
        <group group_id="E3">
          <title>EGb761 120 mg (Open Phase)</title>
          <description>EGb761 120 mg tablet twice a day for 17 months (open phase) for MC and CNE patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastro esophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Essential Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Neurology</name_or_title>
      <organization>Ipsen</organization>
      <phone>clinical.trials@ipsen.com</phone>
      <email>clinical.trials@ipsen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

